Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Global Markets Direct's, Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016', provides in depth analysis on Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2)
- The report reviews Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Overview 7
Therapeutics Development 8
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Stage of Development 8
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Therapy Area 9
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Indication 10
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Companies 13
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Universities/Institutes 15
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Companies Involved in Therapeutics Development 22
Addex Therapeutics Ltd 22
Domain Therapeutics SA 23
Eli Lilly and Company 24
Johnson & Johnson 25
Merck & Co., Inc. 26
Taisho Pharmaceutical Holdings Co., Ltd. 27
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Drug Profiles 28
ADX-92639 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
JNJ-40411813 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
LSN-2535717 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
LY-2607540 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
MGS-0028 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Antagonize mGluR2 for Parkinson's Disease - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Dormant Projects 39
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Discontinued Products 42
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Featured News & Press Releases 43
Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy 43
Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death 43
Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms 44
Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 44
Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 45
Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 47
Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms 48
Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms 48
Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia 49
Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model 50
Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program 51
Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator 51
Jan 17, 2005: Addex Pharmaceuticals Enters Into Collaboration With Ortho-McNeil Pharmaceutical To Develop Novel Treatments For Anxiety, Depression, Schizophrenia And Alzheimer's Disease 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Route of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by Addex Therapeutics Ltd, H1 2016 22
Pipeline by Domain Therapeutics SA, H1 2016 23
Pipeline by Eli Lilly and Company, H1 2016 24
Pipeline by Johnson & Johnson, H1 2016 25
Pipeline by Merck & Co., Inc., H1 2016 26
Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 27
Dormant Projects, H1 2016 39
Dormant Projects (Contd..1), H1 2016 40
Dormant Projects (Contd..2), H1 2016 41
Discontinued Products, H1 2016 42